This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

ITM-55D & ITM-52 for Ovarian Cancer / NSCL Adenocarcinoma

Therapeutic ITM-52 (225Ac-FRαTM*) & diagnostic ITM-55 (18F-AzaFol)

Folate receptor α (FRα) is selectively overexpressed on the cell surface of many different cancers, such as non-small-cell lung carcinoma, ovarian cancer or triple negative breast cancer. Targeted Radionuclide Therapies against (FRα) could be of significant importance for the treatment of patients diagnosed with these tumors.1

ITM-52 (225Ac-FRαTM*) is an innovative Targeted Radionuclide Therapy candidate under investigation for patients suffering from FRα+ tumors.

ITM-52 consists of two molecular components – firstly, actinium-225, a high-energy alpha-emitting radioisotope, and secondly, FRαTM*, a FRα specific folate variant, which is currently nondisclosed. This novel tumor-specific FRα targeting molecule has been designed for labeling with therapeutic actinium-225 as well as the companion diagnostic PET-radioisotope fluorine-18.

The FRα targeting molecules, which are under development, bind with high affinity to FRα, retaining receptor-binding properties when labeled with 225Ac or 18F. ITM-55 (18F-AzaFol) has demonstrated excellent dosimetric results and imaging in a Phase I study in patients with cancer.2 Merck KGaA, a global leader in active pharmaceutical development, exclusively supplies ITM FRα targeting molecules for radiolabeling and clinical development.


* FRαTM = Folate Receptor α (FRα) Targeting Molecule

1 Cheung et al., 2016, Oncotarget 7(32): 52553–52574
2 Schniering et al., 2019, Frontiers in Immunology 10: 2724

Please note: ITM-52 (225Ac-FRαTM) and ITM-55 (18F-AzaFol) are not authorized for marketing in any country at this time.